ImmunisBio-Korea University Guro Hospital, Phase 1/2a Clinical Trial for Gastrointestinal Cancer

Immunis Bio, a developer of advanced biopharmaceuticals, announced on the 14th that it will conduct a Phase 1/2a clinical trial of the autologous NK cell therapy MYJ1633 for the indication of 'gastrointestinal cancer with confirmed peritoneal metastasis' in collaboration with Professor Jonghan Kim's team at Korea University Guro Hospital.

Professor Jonghan Kim's team at Korea University Guro Hospital is conducting clinical research on a treatment method that directly administers existing anticancer drugs into the peritoneal cavity for 'advanced or recurrent stomach cancer with peritoneal metastasis.'

They are expanding this treatment method to administer NK cell therapy directly into the peritoneal cavity.

Gastrointestinal cancer occurs in the gastrointestinal tract areas such as the esophagus, stomach, pancreas, liver, gallbladder, bile ducts, small intestine, and colon. All five major cancers with high mortality rates, excluding lung cancer, occur in the gastrointestinal tract. Cancer cells located in the peritoneum spread along the membrane, worsening symptoms, and when tumor nodes are found, it often indicates a serious condition.

This is the first case of an immune cell therapy directly administered into the peritoneal cavity. The trial targets patients with gastric or colorectal cancer who have confirmed peritoneal metastasis and have failed second-line standard chemotherapy. The investigational drug ‘MYJ1633’ will be administered intraperitoneally five times at one-week intervals to verify safety and efficacy.

MYJ1633 is an activated autologous NK cell therapy currently undergoing clinical trials for indications including gastric cancer, breast cancer, and colorectal cancer.

Jung-hwa Kang, CEO of Immunis Bio, stated, "Peritoneal metastatic gastric cancer still has no clear treatment options," and added, "We are confident that this clinical trial will provide new treatment opportunities and hope for patients with peritoneal metastasis."

This content was produced with the assistance of AI translation services.